



(11) **EP 3 137 110 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 72**

(48) Corrigendum issued on:  
**10.08.2022 Bulletin 2022/32**

(45) Date of publication and mention  
of the grant of the patent:  
**06.07.2022 Bulletin 2022/27**

(21) Application number: **15786559.3**

(22) Date of filing: **04.05.2015**

(51) International Patent Classification (IPC):  
**A61K 39/395<sup>(2006.01)</sup> A61P 25/00<sup>(2006.01)</sup>**  
**C07K 16/32<sup>(2006.01)</sup> A61K 39/00<sup>(2006.01)</sup>**

(52) Cooperative Patent Classification (CPC):  
**C07K 16/32; A61P 25/00; A61K 2039/505;**  
**C07K 2317/24; C07K 2317/76**

(86) International application number:  
**PCT/CA2015/050500**

(87) International publication number:  
**WO 2015/164984 (05.11.2015 Gazette 2015/44)**

(54) **ERBB2 SIGNALING AND NERVE REGENERATION**

ERBB2-SIGNALISIERUNG UND NERVENREGENERATION

SIGNALISATION ERBB2 ET RÉGÉNÉRATION NERVEUSE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **02.05.2014 US 201461987692 P**

(43) Date of publication of application:  
**08.03.2017 Bulletin 2017/10**

(73) Proprietor: **The Hospital For Sick Children**  
**Toronto, Ontario M5G 1X8 (CA)**

(72) Inventors:  
• **HENDRY, James M.**  
**Kingston, ON K7M6R4 (CA)**  
• **PLACHETA, Eva**  
**A-1190 Vienna (AT)**  
• **GORDON, Tessa**  
**Toronto, Ontario M5M 1R9 (CA)**  
• **BORSCHER, Gregory H.**  
**Toronto, Ontario M5M 2G8 (CA)**

(74) Representative: **Lecomte & Partners**  
**76-78, rue de Merl**  
**2146 Luxembourg (LU)**

(56) References cited:

- **PLACHETA EVA ET AL: "The ErbB2 inhibitor Herceptin (Trastuzumab) promotes axonal outgrowth four weeks after acute nerve transection and repair", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 582, 8 September 2014 (2014-09-08), pages 81-86, XP029049218, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2014.09.006**
- **J. MICHAEL HENDRY ET AL: "ErbB2 blockade with Herceptin (trastuzumab) enhances peripheral nerve regeneration after repair of acute or chronic peripheral nerve injury : Herceptin and Regeneration", ANNALS OF NEUROLOGY., vol. 80, no. 1, 6 June 2016 (2016-06-06), pages 112-126, XP055409406, BOSTON, US ISSN: 0364-5134, DOI: 10.1002/ana.24688**
- **HUNG-MING CHANG ET AL: "Neuregulin Facilitates Nerve Regeneration by Speeding Schwann Cell Migration via ErbB2/3-Dependent FAK Pathway", PLOS ONE, vol. 8, no. 1, 2 January 2013 (2013-01-02), page e53444, XP055409408, DOI: 10.1371/journal.pone.0053444**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 137 110 B8**

- GIULIA RONCHI ET AL: "ErbB2 Receptor Over-Expression Improves Post-Traumatic Peripheral Nerve Regeneration in Adult Mice", PLOS ONE, vol. 8, no. 2, 21 February 2013 (2013-02-21), page e56282, XP055409534, DOI: 10.1371/journal.pone.0056282
- FLORENCE R FRICKER ET AL: "The role of neuregulin-1 in the response to nerve injury", FUTURE NEUROLOGY, vol. 6, no. 6, 1 November 2011 (2011-11-01), pages 809-822, XP055409538, GB ISSN: 1479-6708, DOI: 10.2217/fnl.11.45
- BASELGA, J. ET AL.: 'Mechanism of action of Trastuzumab and scientific update' SEMINARS IN ONCOLOGY vol. 28, October 2001, pages 4 - 11, XP008185063
- PLACHETA, E. ET AL.: 'The ErbB2 inhibitor Herceptin (Trastuzumab) promotes axonal outgrowth four weeks after acute nerve transection and repair' NEUROSCIENCE LETTERS vol. 582, October 2014, ISSN 1872-7972 pages 81 - 86, XP029049218
- RAIMONDO, S. ET AL.: 'Schwann cell behaviour after nerve repair by means of tissue-engineered muscle-vein combined guides' J. COMPARATIVE NEUROLOGY vol. 489, August 2005, ISSN 0021-9967 pages 249 - 259, XP055233967
- ATANASOSKI, S. ET AL.: 'ErbB2 signaling in Schwann cells is mostly dispensable for maintenance of myelinated peripheral nerves and proliferation of adult Schwann cells after injury' J. NEUROSCIENCE vol. 26, February 2006, ISSN 1529-2401 pages 2124 - 2131, XP055233969